来氟米特用于治疗类风湿关节炎。

Bulletin on the rheumatic diseases Pub Date : 1999-01-01

N J Olsen, V Strand, J M Kremer

{"title":"来氟米特用于治疗类风湿关节炎。","authors":"N J Olsen, V Strand, J M Kremer","doi":"","DOIUrl":null,"url":null,"abstract":"Leflunomide treatment appears to offer an alternative to methotrexate and sulfasalazine and is a welcome addition to the therapeutic armamentarium for treating active RA. Leflunomide treatment for more than 12 months results in clinically meaningful improvements in disease-specific measures of physical function. The phase 3 trials have shown leflunomide to be as effective as methotrexate and sulfasalazine and an option for initial DMARD therapy. As with all new agents, the long-term safety and value of leflunomide will be determined by use in the clinic.","PeriodicalId":75657,"journal":{"name":"Bulletin on the rheumatic diseases","volume":"48 8","pages":"1-4"},"PeriodicalIF":0.0000,"publicationDate":"1999-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Leflunomide for the treatment of rheumatoid arthritis.\",\"authors\":\"N J Olsen, V Strand, J M Kremer\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Leflunomide treatment appears to offer an alternative to methotrexate and sulfasalazine and is a welcome addition to the therapeutic armamentarium for treating active RA. Leflunomide treatment for more than 12 months results in clinically meaningful improvements in disease-specific measures of physical function. The phase 3 trials have shown leflunomide to be as effective as methotrexate and sulfasalazine and an option for initial DMARD therapy. As with all new agents, the long-term safety and value of leflunomide will be determined by use in the clinic.\",\"PeriodicalId\":75657,\"journal\":{\"name\":\"Bulletin on the rheumatic diseases\",\"volume\":\"48 8\",\"pages\":\"1-4\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"1999-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Bulletin on the rheumatic diseases\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Bulletin on the rheumatic diseases","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

来氟米特治疗似乎是甲氨蝶呤和柳氮磺胺嘧啶的一种替代品，是治疗活动性类风湿性关节炎的一种受欢迎的治疗手段。来氟米特治疗12个月以上可使疾病特异性身体功能指标有临床意义的改善。3期试验表明来氟米特与甲氨蝶呤和柳氮磺胺嘧啶一样有效，是初始DMARD治疗的一种选择。与所有新药物一样，来氟米特的长期安全性和价值将通过临床使用来确定。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Leflunomide for the treatment of rheumatoid arthritis.

Leflunomide treatment appears to offer an alternative to methotrexate and sulfasalazine and is a welcome addition to the therapeutic armamentarium for treating active RA. Leflunomide treatment for more than 12 months results in clinically meaningful improvements in disease-specific measures of physical function. The phase 3 trials have shown leflunomide to be as effective as methotrexate and sulfasalazine and an option for initial DMARD therapy. As with all new agents, the long-term safety and value of leflunomide will be determined by use in the clinic.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Bulletin on the rheumatic diseases

自引率

0.00%

发文量

期刊最新文献

Update on reactive arthritis. Sensible approach to low back pain. The use of low-dose prednisone in the management of rheumatoid arthritis. Getting to the heart of the matter in systemic lupus and rheumatoid arthritis. Sex and arthritis.